|
Oct 9
|
Ligand Pharmaceuticals Inc (LGND) Q2 2024 Earnings Call Highlights: Robust Revenue Growth Amid ...
|
|
Oct 9
|
LGND: Initiating Coverage – A Prince Among Royalty
|
|
Jul 23
|
Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jun 14
|
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
|
|
Jun 14
|
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
|
|
Jun 14
|
What Makes Ligand (LGND) a New Strong Buy Stock
|
|
May 23
|
Ligand to Participate in Upcoming Investor Conferences
|
|
May 21
|
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
|
|
May 21
|
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
|
|
May 21
|
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
|
|
Mar 28
|
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
|
|
Mar 26
|
Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know
|
|
Jan 11
|
Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights
|
|
Jan 11
|
Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene
|
|
Dec 27
|
13 Most Promising Small-Cap Stocks According to Analysts
|
|
Dec 8
|
Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?
|
|
Dec 6
|
Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City
|
|
Dec 1
|
Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock
|
|
Dec 1
|
Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications
|
|
Nov 28
|
Tharimmune (THAR) Up on Positive Data From Pipeline Candidate
|